BTN1A1 and YAP1 Expression as Biomarkers in Colon Cancer: Phase 1b Trial Results of hSTC810

Nelmastobart combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial

BTN1A1 expression in colon cancer: Implications for immunotherapy and patient stratification

Spatial Biology Insights into Simultaneous Targeting of BTN1A1 and YAP in Cancer: Enhanced Efficacy in 3D Cultures and Clinical Trials I and Ib

First-in-Human Study of Nelmastobart (hSTC810), an Anti-BTN1A1 Antibody, in Advanced Solid Tumor Patients

The effect of butyrophilin 1A1 (BTN1A1) blockade in combination with radiation treatment in tumor models

BTN1A1 regulates T cell-mediated cancer immunotherapy by interacting with Galectin-9

The effect of butyrophilin 1A1 (BTN1A1) blockade in combination with radiation treatment in tumor models

BTN1A1-Targeted Immunotherapy in combination with Standard of Care Therapy in Small Cell Lung and Colorectal Cancers

Update on the Phase 1 trial of Nelmastobart in patients with advanced solid tumors